Health Plans Ask 2nd Circ. To Revive Celgene Cancer Drug Row
Health plans and pharmacies backed by Cigna are asking the Second Circuit to revive a proposed class action alleging Bristol-Myers Squibb Co. and its Celgene subsidiary fraudulently obtained patents, filed sham...To view the full article, register now.
Already a subscriber? Click here to view full article